News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Yuji Uehara: Morning immuno-chemotherapy nearly doubled survival in NSCLC
Yuji Uehara/X
Mar 3, 2025, 11:31

Yuji Uehara: Morning immuno-chemotherapy nearly doubled survival in NSCLC

Yuji Uehara, Medical Oncologist at National Cancer Center Japan, shared a post on X about a paper by Zhe Huang et al. published in eBioMedicine:

“Timing might matter in NSCLC! A bi-continental study shows morning immuno-chemotherapy (before 11:30 AM) nearly doubled survival vs afternoon dosing (33.0 vs 19.5 months). RWE from France and China – time to rethink the schedule of immunotherapy!”

“Overall survival according to time-of-day of combined immuno-chemotherapy for advanced non-small cell lung cancer: a bicentric bicontinental study”

Authors: Zhe Huang, Abdoulaye Karaboué, Liang Zeng, Yongchang Zhang, Francis Lévi et al.

Yuji Uehara: Morning immuno-chemotherapy nearly doubled survival in NSCLC

More posts featuring Yuji Uehara.

Abdoulaye Karaboué cancer Francis Lévi Liang Zeng non small cell lung cancer NSCLC OncoDaily Oncology Yongchang Zhang Yuji Uehara Zhe Huang
Special Coverage
Career
Apr 24, 2025, 21:39
Triparna Sen: I am thrilled and humbled to be nominated as a candidate for the IASLC Board of Directors
Blog
Apr 24, 2025, 21:05
Liz O’Riordan: 25 things I wish I had known before I got breast cancer
Blog
Apr 24, 2025, 20:53
Signing Ceremony of MoU Between Doha University for Science and Technology and Qatar Cancer Society
Blog
Apr 24, 2025, 20:40
Yan Leyfman: How AI is transforming cancer care - from improving diagnosis to reducing disparities
Insight
Apr 24, 2025, 20:28
Fernando Campos: We revealed a harsh Brazilian reality in Sarcoma Study
Insight
Apr 24, 2025, 19:38
George Vlachogiannis: Black patients were less likely to receive nephrectomy compared to non-Hispanic White patients
Blog
Apr 24, 2025, 18:30
Paolo Tarantino: Recent ADCs took a median time of 7 years from clinical introduction to approval
Blog
Apr 24, 2025, 17:56
Milestones from Philippine Cervical Cancer Elimination Operational Plan Workshop - APAC Women's Cancer Coalition
Blog
Apr 24, 2025, 17:55
Julie S. Torode: Attending my first ever AACR conference this week - long over due
Blog
Apr 24, 2025, 17:41
The Ohio State’s James Cancer Hospital and Solove Research Institute Welcomes Dr. Kimryn Rathmell as New CEO
Blog
Apr 24, 2025, 17:36
Bishal Gyawali: WHO EML working group discussion on checkpoint inhibitors for solid cancers
Blog
Apr 24, 2025, 17:27
Shane Jacobson: I had the chance to celebrate Dave Coulier being cancer free and now an Ambassador for the V Foundation